120 related articles for article (PubMed ID: 30540926)
1. Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis.
Yuan G; Lian Z; Liu Q; Lin X; Xie D; Song F; Wang X; Shao S; Zhou B; Li C; Li M; Yao G
Cancer Lett; 2019 Feb; 443():135-144. PubMed ID: 30540926
[TBL] [Abstract][Full Text] [Related]
2. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Mallon R; Hollander I; Feldberg L; Lucas J; Soloveva V; Venkatesan A; Dehnhardt C; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Gibbons J
Mol Cancer Ther; 2010 Apr; 9(4):976-84. PubMed ID: 20371716
[TBL] [Abstract][Full Text] [Related]
4. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract][Full Text] [Related]
5. Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts.
Feng MX; Hong JX; Wang Q; Fan YY; Yuan CT; Lei XH; Zhu M; Qin A; Chen HX; Hong D
Sci Rep; 2016 Jan; 6():19074. PubMed ID: 26743690
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
7. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
8. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
9. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
Wander SA; Zhao D; Besser AH; Hong F; Wei J; Ince TA; Milikowski C; Bishopric NH; Minn AJ; Creighton CJ; Slingerland JM
Breast Cancer Res Treat; 2013 Apr; 138(2):369-81. PubMed ID: 23430223
[TBL] [Abstract][Full Text] [Related]
10. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
11. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
[TBL] [Abstract][Full Text] [Related]
12. Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling.
Hsieh CJ; Kuo PL; Hou MF; Hung JY; Chang FR; Hsu YC; Huang YF; Tsai EM; Hsu YL
Int J Oncol; 2015 Feb; 46(2):555-62. PubMed ID: 25421824
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction.
Xie G; Liu W; Lian Z; Xie D; Yuan G; Ye J; Lin Z; Wang W; Zeng J; Shen H; Wang X; Feng H; Cong W; Yao G
Biochem Pharmacol; 2021 Jun; 188():114579. PubMed ID: 33895161
[TBL] [Abstract][Full Text] [Related]
16. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
Chun J; Kim YS
Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
[TBL] [Abstract][Full Text] [Related]
17. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
18. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
20. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
